Ertapenem

Evidence Level: L3

Predicted Indications: 10

Ertapenem
Ertapenem: From Complicated Bacterial Infections to Bacterial Arthritis

## Pharmacist Assessment Report

Ertapenem: From Complicated Bacterial Infections to Bacterial Arthritis

One-Sentence Summary

Ertapenem is a broad-spectrum carbapenem antibiotic with established use against complicated intra-abdominal, skin/soft-tissue, and urinary tract infections. The TxGNN model predicts it may also be effective for Bacterial Arthritis (septic arthritis), a direction currently supported by 0 registered clinical trials but 8 relevant publications (mostly case reports and retrospective cohorts).

Data caveat: This evidence pack’s original_indications field is empty and original_moa is a data gap. One of the other candidates in this pack (rank 7, urinary tract infection) is explicitly flagged internally as an already-approved indication for Ertapenem elsewhere — meaning it is not a genuine new use but an artifact of missing baseline-indication data. Bacterial arthritis, by contrast, is not a labeled indication and represents a real off-label repurposing signal.

Quick Overview

Item	Content
Original Indication	Not on file — Ertapenem holds no Taiwan license (0 authorizations); internal data flags urinary tract infection as an indication already approved for Ertapenem elsewhere, indicating this is a data gap rather than a drug with no prior indications
Predicted New Indication	Bacterial Arthritis
TxGNN Prediction Score	99.72%
Evidence Level	L3
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Ertapenem in this evidence pack. Based on known information, Ertapenem is a broad-spectrum carbapenem (β-lactam) antibiotic with bactericidal activity against most Enterobacteriaceae (including ESBL producers), several anaerobes, and methicillin-susceptible Staphylococcus aureus (MSSA). Its established efficacy spans complicated intra-abdominal infections, skin/soft-tissue infections, complicated urinary tract infections, and community-acquired pneumonia.

Bacterial (septic) arthritis is caused predominantly by the same organism classes Ertapenem already targets — Enterobacteriaceae, anaerobes, and MSSA — so extending its use to joint-space infections is a pharmacologically plausible extension rather than a novel mechanism. This is reinforced by Ertapenem’s once-daily dosing and long half-life, which make it well suited to the prolonged outpatient parenteral antimicrobial therapy (OPAT) regimens that bone and joint infections typically require.

Real-world practice already reflects this overlap: retrospective cohorts and multiple pathogen-specific case reports (Klebsiella, Citrobacter, Clostridium, Prevotella) describe Ertapenem being used successfully to treat septic arthritis and osteomyelitis, even though no prospective randomized trial has tested it as a primary treatment for bacterial arthritis specifically. This is why the evidence level sits at L3 (observational/case evidence) rather than L1/L2.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
24709258	2014	Retrospective cohort	Antimicrob Agents Chemother	Among 306 outpatients on long-term ertapenem OPAT, bone and joint infections were a common indication alongside intra-abdominal infections and pneumonia
31220276	2019	Retrospective cohort	J Antimicrob Chemother	Cohort of 10 patients on subcutaneous suppressive β-lactam therapy (including ertapenem) for prosthetic joint infection/chronic osteomyelitis, used as off-label salvage therapy
39193962	2024	Epidemiological/retrospective	Clin Lab	Pathogen distribution and antimicrobial resistance analysis in bone and joint infections in young children
31352398	2019	Case report	BMJ Case Reports	Citrobacter koseri osteomyelitis with concomitant gouty arthritis in a diabetic patient, successfully treated with ertapenem
31585203	2020	Case report	Anaerobe	First reported case of Clostridium paraputrificum native shoulder septic arthritis and osteomyelitis
22233826	2011	Case report	J Chemother	Klebsiella pneumoniae septic wrist arthritis successfully treated with ertapenem plus levofloxacin
37578166	2023	Case report	J Investig Med High Impact Case Rep	Prevotella bivia septic arthritis of the knee in an immunocompetent adult
38924836	2024	In vitro/preclinical	Diagn Microbiol Infect Dis	Auranofin restores ertapenem susceptibility against carbapenem-resistant E. coli via synergy (mechanistic, not arthritis-specific)

Safety Considerations

Please refer to the SmPC for safety information. Note: this evidence pack flags TFDA labeling data (warnings/contraindications) as a blocking data gap (DG001) — a formal S1 safety review cannot proceed until this is obtained, and no drug-drug interaction data was found in the queried source.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence for bacterial arthritis is limited to retrospective cohorts and case reports (L3) with no clinical trials or prospective studies, and Ertapenem currently holds no Taiwan marketing authorization. A blocking safety data gap (missing TFDA warnings/contraindications) also prevents completion of the mandatory S1 safety screen.

To proceed, the following is needed:

TFDA-equivalent label data (warnings, contraindications) to close blocking gap DG001
Detailed mechanism of action documentation from DrugBank to close gap DG002
Clarification of Ertapenem’s Taiwan/global original-indication set, since the current data gap caused urinary tract infection to be mis-flagged as a “new” indication when it is already approved elsewhere
A prospective or larger comparative study specifically in bacterial/septic arthritis to move evidence from L3 toward L1/L2 before any Guardrails-based proceed decision
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.